Opendata, web and dolomites

SYST-iMYC SIGNED

Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SYST-iMYC project word cloud

Explore the words cloud of the SYST-iMYC project. It provides you a very rough idea of what is the project "SYST-iMYC" about.

clinically    vivo    suppression    feasibility    normal    tissues    trials    establishing    transferred    mutant    drug    types    unfeasible    treatment    commercialization    designed    found    dogma    inhibitor    risk    local    redundant    patients    mouse    unexpected    market    lymphoma    contributes    reaching    omomyc    cog    spin    melanoma    soucek    deg    indications    limited    cancers    cell    multiple    tumorigenesis    erc    annually    breast    therapies    current    inhibit    industrial    de    class    peak    compensated    lung    cells    first    intranasal    dramatic    protected    617473    passing    systemic    resistance    polypeptide    myc       off    direct    ing    estimations    cellular    potentially    critically    models    clinical    catastrophic    vitro    immune    tumorigenic    poc    active    tumors    thanks    cancer    dr    612    human    patent    causing    probability    anti    innovative    functions    revenue    purified    enter    therapeutic    showed    commercial    variant    discovered    data    penetrating    reversible    continue    inhibition    2013    emergence    forecasted    company    brain    wanted    milestones    ready   

Project "SYST-iMYC" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON 

Organization address
address: CALLE NAZARET 115-117
city: BARCELONA
postcode: 8035
website: http://www.vhio.net

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 148˙875 €
 EC max contribution 148˙875 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) coordinator 148˙875.00

Map

 Project objective

Current cancer therapies target redundant cellular functions often compensated for by cancer cells, resulting in resistance to treatment. Here we propose an innovative approach to inhibit Myc, a non-redundant and “most-wanted” therapeutic target for human cancer. Targeting Myc has long been considered unfeasible because of the potentially catastrophic side effects in normal tissues. Against this dogma, we showed that Myc inhibition by Omomyc, a Myc mutant designed by Dr. Soucek, has a dramatic therapeutic impact in multiple mouse models of cancer, while causing only limited and reversible side effects. Critically, there is no emergence of resistance. Thanks to the ERC-2013-CoG n° 617473, we discovered the unexpected cell-penetrating properties of the purified Omomyc polypeptide. Moreover, we found that it is anti-tumorigenic after local (intranasal) delivery to mouse models of lung and brain tumors, and could therefore become the first clinically-viable direct Myc inhibitor. With this ERC PoC, we propose to develop a new drug based on an Omomyc variant that enables systemic treatment of several cancer types including lymphoma, breast, and melanoma. In all these cancers Myc contributes to multiple aspects of tumorigenesis including immune suppression. At the end of this project we will have a patent protected therapeutic polypeptide active in vitro and in vivo and ready to enter clinical trials Phase I/II in patients and to continue its commercialization. The forecasted peak revenue for such first-in-class drug in those indications reaches 2.612 M€ annually. With this ERC PoC project we will achieve essential milestones to develop this innovative therapeutic polypeptide by establishing the feasibility, including a commercial data package and cost estimations for the industrial production. Passing these milestones will de-risk the product and increase its value and probability of reaching the market by making it ready to be transferred to a spin-off company.

 Publications

year authors and title journal last update
List of publications.
2019 Mireia Pesarrodona, Toni Jauset, Zamira V. Díaz‐Riascos, Alejandro Sánchez‐Chardi, Marie‐Eve Beaulieu, Joaquin Seras‐Franzoso, Laura Sánchez‐García, Ricardo Baltà‐Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz, Laura Soucek, Antonio Villaverde, Ibane Abasolo, Esther Vázquez
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies
published pages: 1900849, ISSN: 2198-3844, DOI: 10.1002/advs.201900849
Advanced Science 6/18 2020-03-05
2019 S. Ramón y Cajal, P. Sancho, L. Soucek, H. Peinado, M. Abad, M. Valiente, A. Efeyan, J. Pardo, V. Quesada, J. Jimeno, P. M. Duque, A. Antón, I. Varela, A. J. Schuhmacher
A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas
published pages: , ISSN: 1699-048X, DOI: 10.1007/s12094-019-02199-4
Clinical and Translational Oncology 2020-02-28
2018 Sílvia Casacuberta-Serra, Laura Soucek
Myc and Ras, the Bonnie and Clyde of immune evasion
published pages: S457-S459, ISSN: 2218-676X, DOI: 10.21037/tcr.2018.03.09
Translational Cancer Research 7/S4 2020-02-28
2019 Marie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Peter Rahl, Loïka Maltais, Mariano F. Zacarias-Fluck, Sílvia Casacuberta-Serra, Erika Serrano del Pozo, Christopher Fiore, Laia Foradada, Virginia Castillo Cano, Meritxell Sánchez-Hervás, Matthew Guenther, Eduardo Romero Sanz, Marta Oteo, Cynthia Tremblay, Génesis Martín, Danny Letourneau, Martin Montagne, Migu
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
published pages: eaar5012, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aar5012
Science Translational Medicine 11/484 2020-02-28
2019 Jonathan Whitfield, Laura Soucek
Editorial overview: Peptides in cancer
published pages: iii-v, ISSN: 1471-4892, DOI: 10.1016/j.coph.2019.06.001
Current Opinion in Pharmacology 47 2020-02-28
2019 Marie-Eve Beaulieu, Laura Soucek
Finding MYCure
published pages: e1618178, ISSN: 2372-3556, DOI: 10.1080/23723556.2019.1618178
Molecular & Cellular Oncology 6/5 2020-02-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYST-IMYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYST-IMYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

SPA4AstroQIT (2019)

Broadband Quantum-Limited Parametric Amplifier for Astronomy and Quantum Information Technology

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More